How many drugs treat Punctate keratitis?

Drug Landscape tracks 6 marketed treatments for Punctate keratitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/punctate-keratitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Punctate keratitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Punctate keratitis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Punctate keratitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1998-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Lotemax	Lotemax	Tufts Medical Center		Glucocorticoid receptor
Nebcin	Nebcin	University Hospital, Lille		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Punctate keratitis
Bausch Health · 1 drug in Punctate keratitis
Generic (originally Merck) · 1 drug in Punctate keratitis
Novartis · 1 drug in Punctate keratitis
Pfizer · 1 drug in Punctate keratitis
Tufts Medical Center · 1 drug in Punctate keratitis
University Hospital, Lille · 1 drug in Punctate keratitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Punctate keratitis:

Cite this brief

Drug Landscape (2026). Punctate keratitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/punctate-keratitis. Accessed 2026-06-10.

Punctate keratitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing